ESTRO 2025 - Abstract Book

S2320

Interdisciplinary – Health economics & health services research

ESTRO 2025

3547

Digital Poster Wearables: are they for all and are they the answer to continuous monitoring during and after radiotherapy? Phil Fendall Amaro 1 , Louise McHugh 1 , Lee Whiteside 1 , Rachael Bailey 1 , Jacqui Bridge 1 , Alan McWilliam 2 , Kathryn Banfill 3 , Anthony Wilson 4 , Shermaine Pan 3 1 Radiotherapy, The Christie NHS Foundation Trust, Manchester, United Kingdom. 2 Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom. 3 Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. 4 Anaesthesia and Critical Care, Manchester University NHS Foundation Trust, Manchester, United Kingdom Purpose/Objective: Digital health devices are a potentially cost-efficient method to monitor health and improve patient outcomes. Such technology has the advantage of providing continuous, longitudinal data. However, there is limited evidence pertaining to the equitable introduction of these innovations. We present a comparative analysis of recruitment to two studies utilising digital technology to monitor wellbeing during and after radiotherapy. Material/Methods: The Remote Cardiac mOnitoring following lung RaDiotherapy (ReCoRd) study (IRAS 289962) ran between Nov 2021 Dec 2023, whilst cohort 4 of Enhanced Monitoring for Better Recovery and Cancer Experience in Greater Manchester (EMBRACe-GM) study (IRAS 294391) is ongoing, recruiting since Jul 2023. Both studies analysed the use of wearable health monitoring devices including the Withing’s SmartWatch (model: HWA09, Withings, France) and additionally the Oura ring (model: Balance, Oura Health, Finland) for EMBRACe-GM. ReCoRd recruited participants with lung cancer receiving photon radiotherapy, whilst EMBRACe-GM cohort 4 recruited participants receiving PBT for head, neck and CNS cancers. Between the studies, screening logs were analysed for patient age and enrolment status. Patient satisfaction and device comfort was assessed via questionnaires completed during the treatment period for both studies. Results: 49 participants were recruited to ReCoRd, whilst 21 were recruited to EMBRACe-GM cohort 4. Within EMBRACe-GM the median age of those approached was 27 years (16-69) a significantly younger cohort than those approached for ReCoRd at 71 years (47-89) (figure 1).